National Medical Research Center for Therapy and Preventive Medicine; Medical Research and Educational Center, Lomonosov Moscow State University.
Privolzhsky Research Medical University.
Kardiologiia. 2022 Apr 30;62(4):12-19. doi: 10.18087/cardio.2022.4.n1997.
Aim To study true prevalence of atrial fibrillation (AF) in a representative sample from the European part of the Russian Federation; to describe characteristics of patients with AF; and to provide the frequency of anticoagulant treatment.Material and methods Cross-sectional data of the EPOCH epidemiological study (2017) were used. Data were collected in 8 constituent entities of the Russian Federation; the sample size was 11 453 people. The sample included all respondents who had given their consent for participation and were older than 10 years. Statistical tests were performed in the R system for statistical data analysis.Results The prevalence of AF in the representative sample from the European part of the Russian Federation was 2.04 %. The AF prevalence increased with age and reached a maximum value of 9.6% in the age group of 80 to 89 years. The AF prevalence among females was 1.5 times higher than among men. With age standardization, the AF prevalence was 18.95 and 21.33 per 1,000 people for men and women, respectively. The AF prevalence increased in the presence of concurrent cardiovascular diseases (CVDs) or diabetes mellitus as well as with an increased number of comorbidities in the same person and reached 70.3 and 60.0 % in patients with 4 and 5 comorbidities, respectively. Patients with AF had a greater number of comorbidities and higher CHA2DS2VASc scores (5.0 vs. 2.0, p<0.001) compared to patients with CVDs without AF. Only 22.6 % of patients with CVD and AF took anticoagulants. Only 23.9% of patients with absolute indications for the anticoagulant treatment received anticoagulants.Conclusion The AF prevalence in the European part of the Russian Federation was 2.04 %; it increased with age and in patients with concurrent CVDs or diabetes mellitus. Most of AF patients (93.2 %) required a mandatory treatment with oral anticoagulants.
目的 研究俄罗斯欧洲部分代表性样本中房颤(AF)的真实患病率;描述 AF 患者的特征;并提供抗凝治疗的频率。
材料与方法 使用 EPOCH 流行病学研究(2017 年)的横断面数据。数据来自俄罗斯联邦的 8 个组成实体,样本量为 11453 人。样本包括所有同意参与并年龄在 10 岁以上的受访者。统计检验在 R 系统中进行。
结果 在俄罗斯欧洲部分的代表性样本中,AF 的患病率为 2.04%。AF 的患病率随着年龄的增长而增加,在 80 至 89 岁年龄组达到最高值 9.6%。女性 AF 的患病率是男性的 1.5 倍。年龄标准化后,男性和女性的 AF 患病率分别为每 1000 人 18.95 和 21.33 例。在患有心血管疾病(CVDs)或糖尿病的情况下,AF 的患病率会增加,并且在同一人中有更多的合并症时,AF 的患病率会增加,在患有 4 种和 5 种合并症的患者中,AF 的患病率分别达到 70.3%和 60.0%。与无 AF 的 CVD 患者相比,AF 患者有更多的合并症和更高的 CHA2DS2VASc 评分(5.0 比 2.0,p<0.001)。只有 22.6%的 CVD 和 AF 患者服用抗凝剂。只有 23.9%有绝对抗凝治疗指征的患者接受了抗凝治疗。
结论 俄罗斯欧洲部分的 AF 患病率为 2.04%;它随着年龄的增长而增加,并在患有并发 CVD 或糖尿病的患者中增加。大多数 AF 患者(93.2%)需要强制性使用口服抗凝剂治疗。